Today at CPHI Europe 2025 in Frankfurt, regulatory strategy and scientific rigor were in sharp focus as industry thought leaders responded to escalating regulatory challenges affecting excipients—a cornerstone of pharmaceutical manufacturing and formulation. In an exclusive transcripted interview, Nigel Langley, Global Technical Director of Life Sciences at gChem and the immediate past chair of IPEC-Americas, detailed the evolving landscape confronting producers, suppliers, and regulatory teams managing traditional pharmaceutical excipients. Langley's remarks are particularly relevant for executive leadership, R&D heads, and regulatory compliance professionals as multiple recent regulatory actions in Europe have upended excipient usage norms, product formulations, and supply chain planning.

Langley cites gChem's launch at CPHI of Procipient dimethyl sulfoxide (DMSO), a high-purity, pharmaceutical-grade excipient with established regulatory documentation—including a type two drug master file in the US and type one file in Canada—as an example of proactive innovation and future-proof product stewardship. Additionally, other DMSO grades are promoted for API and peptide synthesis, as well as laboratory diagnostics, further underscoring the role of analytical equipment and reagents in regulatory response and formulation flexibility. CPHI Europe is thus positioned not just as a showcase for new products but as an arena where regulatory affairs and strategic risk mitigation converge, offering direct value to contract manufacturing organizations (CMOs), procurement teams, and supply chain managers.

Highlighting the "daily shift" of regulatory scrutiny surrounding excipients, Langley enumerated the widespread industry disruptions generated by recent concerns—such as restrictions around titanium dioxide (TiO2), anxieties over nitrosamines, growing regulatory attention to microplastics, and PFAS (per- and polyfluoroalkyl substances). The challenge for pharmaceutical industry stakeholders lies both in anticipating the next regulatory target and in marshalling the scientific evidence to defend industry positions and maintain continuity of supply. Langley’s account of the European proposal to ban TiO2 in drug products demonstrates the magnitude of supply chain and manufacturing risk: according to his analysis, approximately 90,000 drug products in Europe would have needed reformulation had the ban been enforced. What’s more, for many generic drugs, the economics of reformulation simply do not add up, risking widespread shortage and market withdrawal.

Langley describes the coordinated industry response—a fact-based, non-emotional presentation of robust scientific evidence—to counter questionable or isolated studies driving regulatory agendas. The European industry mobilized to challenge the citations supporting the ban, ultimately succeeding in keeping TiO2 available for pharma products in many jurisdictions. He suggests this model—leveraging interdisciplinary teams combining regulatory expertise, analytical science, and supply chain intelligence—is the future of effective compliance management for manufacturing enterprises, contract service providers, and CROs. The case not only highlights data-driven advocacy but underscores the importance of maintaining strategic relationships with regulatory bodies and investing in high-caliber scientific advisory capabilities.

For pharmaceutical executives evaluating risk management strategies, Langley’s message is clear: proactive engagement with evolving regulatory trends, continuous monitoring of substance reviews, and methodical data collation are indispensable. This becomes all the more critical within larger organizations overseeing diverse portfolios and cross-border operations, where the regulatory landscape is increasingly fragmented and unpredictable. From laboratory automation teams to packaging engineers and legal compliance departments, the ripple effects of excipient regulation touch every node of the value chain. CPHI Europe 2025 participants are encouraged to reassess their regulatory resilience plans, strengthen multi-stakeholder communications across their organizations, and prioritize the integration of sound science into their commercial and compliance strategies.

With ongoing scrutiny of ingredients like synthetic color additives and talc in the US, and the active roles of organizations such as IPEC in responding to these challenges, the interview serves as a strong call to action for continuous collaboration and resource pooling in the face of relentless regulatory churn. As pharmaceutical manufacturing enters the final quarter of 2025, the insights and strategic frameworks exchanged at CPHI Europe are poised to shape executive decision-making—underscoring the business imperative for rigorous science, methodical advocacy, and robust risk mitigation in the European pharmaceutical sector.